These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19430980)

  • 1. Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.
    Demina TL; Khachanova NV; Davydovskaya MV; Popova NF; Gusev EI
    Neurosci Behav Physiol; 2009 Jun; 39(5):497-9. PubMed ID: 19430980
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 4. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
    Bencsik K; Rajda C; Füvesi J; Járdánházy T; Török M; Vécsei L
    Swiss Med Wkly; 2002 May; 132(17-18):237. PubMed ID: 12087490
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction.
    Owens GM
    J Manag Care Pharm; 2013; 19(1 Suppl A):S3. PubMed ID: 23383727
    [No Abstract]   [Full Text] [Related]  

  • 7. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
    Barnes CJ; Caon C; Foley JF; Friedman M; Menzin J; Nair KV; Nichols C; Olvey EL; Owens GM; Pill MW; Skrepnek GH; White LA; Zerkowski K
    J Manag Care Pharm; 2013; 19(1 Suppl A):S1-53. PubMed ID: 23383730
    [No Abstract]   [Full Text] [Related]  

  • 8. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
    Hohlfeld R
    Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 11. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002].
    Cendrowski W
    Neurol Neurochir Pol; 2002; 36(6):1260-3. PubMed ID: 12715704
    [No Abstract]   [Full Text] [Related]  

  • 12. Treat early, but treat hard: Interferon-beta dose makes a difference.
    Mikol DD
    J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
    [No Abstract]   [Full Text] [Related]  

  • 13. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 15. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
    Chofflon M; Ben-Amor AF
    Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
    [No Abstract]   [Full Text] [Related]  

  • 17. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
    Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multiple sclerosis with interferon beta-1 b.
    Abdul-Ahad A; Shah S; Galazka A
    Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
    [No Abstract]   [Full Text] [Related]  

  • 19. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PRISMS study. Interferon beta-1a therapy in relapsing-remitting multiple sclerosis].
    Limmroth V
    Internist (Berl); 2001 Feb; 42(2):305-7. PubMed ID: 11244885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.